2 documents found, page 1 of 1
Directed disruption of IL2 aggregation and receptor binding sites produces desi...
Dashwood, A; Makuyana, N; Kant, R van der; Ghodsinia, A; Hernandez, AR; S, Lienart; Burton, O; Dooley, J; Ali, M; Kouser, L; Naranjo, F; Holt, MGThe pleotropic nature of interleukin-2 (IL2) has allowed it to be used as both a pro-inflammatory and anti-inflammatory therapeutic agent, through promotion of regulatory T cell (Treg) responses via the trimeric IL2RABG receptor or promotion of CD8 T cell responses via the dimeric IL2RBG receptor, respectively. However, the utility of IL2 as a treatment is limited by this same pleiotropy, and protein engineerin...
Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-...
Yshii, L; Pasciuto, E; Bielefeld, P; Mascali, L; Lemaitre, P; Marino, M; Dooley, J; Kouser, L; Verschoren, S; Lagou, V; Kemps, H; Gervois, P; Boer, AThe ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. Full utility in the neuroinflammation space, however, requires identification of both effective targets for local immune modulation and a delivery system capable of crossing the blood-brain barrier. The recent identification and characterization of a small population of regulatory T (Treg) cells...